CD274 and breast carcinoma: In the phase-II GeparNuevo trial, patients with TN breast cancer were randomized to receive durvalumab, anti-PD-L1 antibody, or placebo followed by nab-paclitaxel and epirubicin/cyclophosphamide [118].